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Abstract
Purpose To assess the presence and pattern of incidental interstitial lung alterations suspicious of COVID-19 on fluorine-18-
fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) ([18F]FDG PET/CT) in asymptomatic
oncological patients during the period of active COVID-19 in a country with high prevalence of the virus.
Methods This is a multi-center retrospective observational study involving 59 Italian centers. We retrospectively
reviewed the prevalence of interstitial pneumonia detected during the COVID period (between March 16 and 27,
2020) and compared to a pre-COVID period (January–February 2020) and a control time (in 2019). The diagnosis of
interstitial pneumonia was done considering lung alterations of CT of PET.
Results Overall, [18F]FDG PET/CT was performed on 4008 patients in the COVID period, 19,267 in the pre-COVID period, and
5513 in the control period. The rate of interstitial pneumonia suspicious for COVID-19 was significantly higher during the
COVID period (7.1%) compared with that found in the pre-COVID (5.35%) and control periods (5.15%) (p < 0.001). Instead, no
significant difference among pre-COVID and control periods was present. The prevalence of interstitial pneumonia detected at
PET/CT was directly associated with geographic virus diffusion, with the higher rate in Northern Italy. Among 284 interstitial
pneumonia detected during COVID period, 169 (59%) were FDG-avid (average SUVmax of 4.1).
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Conclusions A significant increase of interstitial pneumonia incidentally detected with [18F]FDGPET/CT has been demonstrated
during the COVID-19 pandemic. A majority of interstitial pneumonia were FDG-avid. Our results underlined the importance of
paying attention to incidental CT findings of pneumonia detected at PET/CT, and these reports might help to recognize early
COVID-19 cases guiding the subsequent management.
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Introduction
An aggressive acute respiratory disease caused by a novel
coronavirus of zoonotic origin, called COVID-19, occurred
during December 2019 in Wuhan, China, and then spread
everywhere becoming a pandemic. Europe, and especially
Northern Italy, was hit by this infection with the maximum
incidence during March [1, 2]. COVID-19 may present with
no specific signs and symptoms like fever, dyspnea, and
cough, but in most cases, the patients may be also asymptom-
atic. This scenario is the most dangerous because they
can be potential sources of infection for a whole popu-
lation. The exact incidence of asymptomatic patients
remains unclear and yet under debate. Furthermore, it
is well known that often clinical symptoms appear when
the infection is in the peak phase.
Until now, reverse transcriptase-polymerase chain reaction
(RT-PCR) is considered to be the gold standard for the diag-
nosis of COVID-19 infection, but a high false-negative rate is
reported, which can cause a miss or delay in the effective
diagnosis and increase the risk of spread of the epidemic [3].
The reasons of these false negative reports are several: the lack
of shared and standard operation procedures and validation
across different laboratories and hospitals, different disease
stages of infection at time of examination, different viral loads,
and the potential mutation rate of the virus.
Published data [4–6] about the potential role of radiological
tools, such as chest X-rays and computed tomography (CT), in
detecting COVID-19-related interstitial pneumonia are avail-
able, showing good accuracy and describing as typical pattern
of presentation the presence of ground-glass opacities (GGOs)
or bilateral pulmonary consolidations in multiple lobular and
sub-segmental areas [2, 7]. For this reason, some authors sug-
gest considering the combination of clinical, imaging, and
laboratory reports to make the final diagnosis, and in some
cases, the CT morphological pattern seems to be better than
the RT-PCR test [8, 9].
Also fluorine-18-fluorodeoxyglucose positron emission
tomography/CT ([18F]FDG PET/CT) is able to reveal lung
alterations suspicious for COVID-19 pneumonia despite the
sub-optimal diagnostic power of CT (generally low dose) and
several cases of incidental interstitial pneumonia COVID-19-
related detected by [18F]FDG PET/CT in asymptomatic pa-
tients are present in literature [10–19], but these reports are
usually case reports or single-center experience.
The aim of this study was to compare the prevalence of
incidental interstitial pneumonia suspected for COVID-19 in
three different periods (“COVID,” “pre-COVID,” and “con-
trol” periods) in a country with high prevalence of infection
and to describe the main radiological and metabolic features
of this pneumonia during the pandemic time.
Materials and methods
Study design
This is a multi-center retrospective observational study which
saw the participation of 59 centers from all over Italy.
This study was approved by ethics committee (NP 4049) of
ASST Spedali Civili of Brescia.
Population
We retrospectively reviewed the [18F]FDG PET/CT scans
performed in asymptomatic patients for routine oncological
purpose in our centers in three different periods: (a) from
March 16, 2020, to March 27, 2020 (n = 4008), called con-
ventionally “COVID-19 period” being considered a pandemic
time; (b) from January 1, 2020, to February 21, 2020 (n =
19,267), called conventionally “pre-COVID-19 period” con-
sidered a time immediately before the virus spread in
our country; (c) from March 18, 2019, to March 29,
2019 (n = 5513), called conventionally “control period”
considered a COVID-free time being about 1 year be-
fore the pandemic (Fig. 1).
The period from March 9, 2020, was the beginning of the
social containment in Italy with the approval of the national
lockdown; thus, the patients were determined to be asymp-
tomatic for COVID-19 infection verifying body temperature
and excluding any signs or symptoms related to virus infec-
tion by a short anamnesis before accessing the nuclear medi-
cine departments. No suspicion of viral infection was present
in the days before or at the time of the PET/CT scan in any of
our patients. The pre-COVID-19 period was included in our
analysis to investigate if immediately before the official virus
outbreak, COVID-19 was already diffused in the country,
maybe in a subtle way.
Inclusion criteria: patients more than 18 years old at time of
PET/CT scan, patients studied for oncological purposes
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(staging, restaging, or follow-up), patients without any signs
or symptoms suspected for COVID-19 infection at time of
PET/CT or on the days before
Exclusion criteria: patients younger than 18 years old and
patients with concomitant known inflammatory lung diseases
When possible, patients with incidental interstitial pneumo-
nia detected by PET/CT underwent a subsequent nasopharyn-
geal swab by RT-PCR test to confirm the diagnosis of
COVID-19 infection. RT-PCR was performed the same day
or after the scan within 3 days.
We reviewed the medical and pathology reports of the pa-
tients with incidental interstitial pneumonia discovered during
the “COVID period”: epidemiological (age, gender), clinical
(oncological disease, clinical indication of PET/CT), and bio-
chemical (lymphocyte count, erythrocyte sedimentation rate
(ESR) level, C-reactive protein (CRP) level) features,
morphological/radiological pattern by chest CT of PET and
metabolic features by [18F]FDG PET/CT were collected and
analyzed in all patients.
18F-FDG PET/CT imaging and interpretation
All [18F]FDG PET/CT scans were performed following the
international guidelines of the European Association of
Nuclear Medicine [20]. The PET/CT scans were performed
on 69 scanners at the 59 participating centers. The patients
underwent [18F]FDG PET/CT after at least 6 h of fasting
and with glucose level lower than 150 mg/dl.
The injected activity of [18F]FDG was dependent on the
PET scanner used and the patient weight according to local
protocols. Whole-body imaging began at 60 ± 10 min after
radiotracer injection and was acquired from the skull base to
the mid-thigh and reconstructed using attenuation correction.
The PET/CT images were reviewed by local expert
nuclear medicine physicians and if necessary by local
experienced thoracic radiologists. The diagnosis of high-
ly suspicious viral interstitial pneumonia was based on
the findings of pulmonary infiltrates, GGOs, and
subpleural pseudo-nodular mixed ground-glass and con-
solidation areas reviewing chest CT of PET. CT pattern
of lung alterations was considered to define the pres-
ence of pneumonia. Laterality, localization, morphologi-
cal pattern (ground-grass capacities, consolidation areas,
nodules), distribution (peripheral or central, or both),
presence of enlarged thoracic lymph nodes, and pleural
effusion were described for each scan.
Interstitial lung abnormalities were subsequently evaluated
both visually and semiquantitatively by FDG PET/CT.
Every focal tracer uptake deviating from physiological dis-
tribution and with a maximum standardized uptake value
(SUVmax) higher than 2.5 was regarded as positive for
FDG-avidity.
Maximum and mean standardized uptake values
(SUVmax and SUVmean) of the lung abnormalities
and mediastinal lymph nodes were semi-automatically
calculated using local workstation. We measured the
SUV of detectable lesions by drawing a region of inter-
est (ROI) over the area of maximum activi ty.
Furthermore, SUVmax of mediastinum was calculated
at the aortic arch by use of axial PET images with a
round-shaped 10-mm ROI not involving the wall of the
vessel; SUVmax of the liver was calculated at the VIII
hepatic segment of axial PET images using the same
ROI. The ratios between SUVmax of hypermetabolic
lung alterations and SUVmax of mediastinum and liver
were calculated for each patient.
Fig. 1 Flowchart of the cohort selection in the COVID period (a), pre-COVID period (b), and control period (c)
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Statistical analysis
Statistical analyses were performed using MedCalc Software
version 18.1. The descriptive analysis of categorical variables
is characterized by the calculation of simple and relative fre-
quencies, while the numeric variables by median, mean, min-
imum, and maximum values.
Chi-square (χ2) test and Student’s t test were performed to
compare the distributions of categorical and continuous vari-
ables, respectively. To compare the proportions of interstitial
pneumonia observed in the three periods, the McNemar’s test




Overall, [18F]FDG-PET/CT was performed on 4008 patients
in the COVID period, 19,267 in the pre-COVID period, and
5513 in the control period.
In the COVID period, 284/4008 (7.1%) [18F]FDG PET/CT
scans demonstrated the presence of lung abnormalities consis-
tent of interstitial pneumonia, while 1030/19,267 (5.35%) in the
pre-COVID period and 284/5513 (5.15) in the control period
(Fig. 1; Table 1). The rate of interstitial pneumonia was signif-
icantly higher in the COVID period than that in the pre-COVID
and control time (p < 0.001 and p < 0.001, respectively).
Instead, no significant difference among the pre-COVID and
control periods was present (p = 0.569) (Fig. 2a). Similar evi-
dences were derived also considering the prevalence of
[18F]FDG-avid interstitial pneumonia during the COVID peri-
od (4.2% of all examinations) in comparison with pre-COVID
(3.1% of all examinations; p < 0.001) and control (3.1% of all
examinations; p < 0.001) periods (Fig. 2b) and the prevalence
of [18F]FDG-negative interstitial pneumonia during the
COVID period (2.9% of all examinations) in comparison with
pre-COVID (2.25% of all examinations; p = 0.018) and control
(2.1% of all examinations; p = 0.011) periods (Table 1; Fig. 2c).
Among 284 interstitial pneumonia detected during COVID
period, 169 (59%) were FDG-avid showing an increased
[18F]FDG uptake corresponding to the lung abnormalities, while
the remaining 115 (41%) had no significant [18F]FDGuptake. Of
1030 interstitial pneumonia discovered during the pre-COVID
time, 597/1030 (58%) were FDG positive, and the remaining
433 (42%) were negative. In the control period, the interstitial
pneumonia [18F]FDG positive were 170 (59%), and the intersti-
tial pneumonia [18F]FDG negative were 114 (41%). The preva-
lence of [18F]FDG-avidity among all interstitial pneumonia was
not significantly different comparing the three periods.
Macro-area analysis
We conventionally performed a subanalysis dividing all na-
tional data into three geographic macro-areas: Northern Italy,





Number of interstitial pneumonia
FDG+
Number of interstitial pneumonia
FDG−
National data (59 centers)
COVID period 4008 284 (7.1%) 169 (4.2%) 115 (2.9%)
Pre-COVID
period
19,267 1030 (5.35%) 597 (3.1%) 433 (2.25%)
Control period 5513 284 (5.15%) 170 (3.1%) 114 (2.1%)
Northern Italy data (35 centers)
COVID period 2493 196 (7.9%) 117 (4.7%) 79 (3.2%)
Pre-COVID
period
12,716 721 (5.7%) 433 (3.4%) 288 (2.3%)
Control period 3428 191 (5.6%) 112 (3.3%) 79 (2.3%)
Central Italy data (12 centers)
COVID period 674 26 (3.9%) 19 (2.8%) 7 (1.1%)
Pre-COVID
period
3115 91 (2.9%) 63 (2%) 28 (0.9%)
Control period 800 27 (3.4%) 20 (2.5%) 7 (0.9%)
Southern Italy–Islands data (12 centers)
COVID period 841 62 (7.4%) 33 (3.9%) 29 (3.5%)
Pre-COVID
period
3436 278 (6.3%) 101 (2.9%) 117 (3.4%)
Control period 1285 66 (5.1%) 38 (2.9%) 28 (2.2%)
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Central Italy, and Southern Italy and Islands (Supplemental
Fig. 1). Two-thousand four hundred ninety-three [18F]FDG
PET/CT scans were performed in Northern Italy (35 centers)
during the COVID period; in the same period, 674 [18F]FDG
PET/CT scans were acquired in Central Italy (12 centers) and
841 in Southern Italy and Islands (12 centers).
In the COVID period, the prevalences of interstitial pneu-
monia were 7.9% in the Northern Italy, 3.9% in the Central
Italy, and 7.4% in the Southern Italy; in the pre-COVID period
were 5.7%, 2.9%, and 6.3%, respectively; in the control time
5.6%, 3.4%, and 5.1%, respectively (Table 1).
In Northern Italy, the prevalence of interstitial pneumonia
was significantly higher during the COVID period than the
other two time periods (p < 0.001 for both), while no differ-
ence in detection rate between pre-COVID and control pe-
riods (p = 0.825) was registered. For Southern Italy–Islands,
similar evidences were obtained (COVID vs pre-COVID p <
0.001; COVID vs control p < 0.001; pre-COVID vs control
p = 0.005) (Fig. 3).
Instead, considering Central Italy, no significant differ-
ences among interstitial pneumonia detected in the three times
were present (COVID vs pre-COVID p = 0.202; COVID vs
control p = 0.503; pre-COVID vs control p = 0.620) (Fig. 3).
No significant differences considering median age of
patients with interstitial pneumonia in the three macro-
areas were discovered (median age in Northern Italy
68 years, 66 years in Central Italy, and 65 years in
Southern Italy–Islands).
Features of patients with interstitial pneumonia at
the COVID period
he mean age of patients with incidental interstitial pneumonia
detected during COVID-period was 66.3 years (range 18–90),
and there was a prevalence of male gender (n = 159, 56%).
The majority of imaging studies with incidental interstitial
pneumonia suspected for COVID-19 was performed for
diagnosis/staging (n = 144) and restaging/treatment response
evaluation (n = 144); the remaining 34 scans were acquired for
follow-up purpose. The most frequent oncological disease
studied was lung carcinoma (n = 69, 24%), followed by lym-
phoma (n = 60, 21%), and breast (n = 36, 13%) and head and
neck (n = 28, 10%) cancers. The majority of patients
had higher ESR and/or CRP levels, consistent of active
inflammation disease. The main demographic features
are described in Table 2.
Fig. 2 Histogram graphs representing all interstitial pneumonia (a), interstitial pneumonia [18F]FDG positive (b), and interstitial pneumonia [18F]FDG
negative (c) detected in the three periods in the country
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Abnormal CT findings were observed during the pandemic
in 284 patients; in particular, CT abnormalities consisting of
GGOs were registered in 148 cases (52%) and GGOs associ-
ated with consolidation areas in 117 cases (41%). In the re-
maining 19 cases (7%), only consolidation areas (5%) or other
rare signs, like nodules (2%), were reported (Table 3).
Bronchial wall thickening sign was present in 24% and
pleural effusion in 15%. Inmost patients, enlargedmediastinal
lymph nodes were noted. In most cases (65%), more than two
pulmonary lobes were involved, while there was no laterality
prevalence (unilateral pneumonia in 139 patients and bilateral
pneumonia in 145 patients). Among unilateral pneumonia,
there was no prevalence for the right or left lung.
Most of interstitial pneumonia (59%) were FDG-avid show-
ing an increased radiotracer uptake, defined as tracer uptake
higher from physiological distribution and with a SUVmax
higher than 2.5. In all population (interstitial pneumonia
FDG-avid and not avid), the intensity of [18F]FDG uptake, in
terms of SUVmax, ranged between 0.9 and 14.6 (average 4.1),
and in terms of SUVmean ranged between 0.7 and 10 (average
2.6). Average lesion to liver SUVmax ratio and lesion to blood
pool SUVmax ratio were 1.4 (range 0.3–4.7) and 1.9 (0.3–6.8),
respectively. Only in 106 cases (37%) was the presence of
mediastinal lymph nodes FDG-avid registered.
RT-PCR test was performed only in 46 patients (all from
COVID period), being positive in 35 cases (76%) and negative
in the remaining 11 cases (24%). Of 35 RT-PCR–positive pa-
tients, 27 had FDG-avid interstitial pneumonia and the remaining
Fig. 3 Histogram graphs representing all interstitial pneumonia detected in the three periods in the Northern, Central, and Southern Italy
Table 2 The main clinical and demographic features of patients with
interstitial pneumonia detected during “COVID” period
n (%)
Age average±SD (range) 66.3±13.8 (18–90)
Gender F:M 89:159 (44%:56%)
Oncological disease
Lymphoma 60 (21%)




Head and neck 28 (10%)
Melanoma 4 (2%)
Genitourinary 22 (8%)
Other primary 42 (14%)
Indication
Staging/diagnosis 125 (44%)
Restaging/treatment response evaluation 126 (44%)
Follow-up 34 (12%)
Low lymphocyte count 38/118 (32%)
Increased ESR level 25/47 (53%)
Increased CPR level 68/94 (72%)
F, female;M, male; ESR, erythrocyte sedimentation rate;CRP, C-reactive
protein
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8 FDG-negative, while among 11 negative RT-PCR patients, 8
had FDG-avid interstitial pneumonia and the remaining 3
negative.
Discussion
It is well known that the lungs are the most frequent sites of
incidental findings suspicious for COVID-19 at [18F]FDG
PET/CT, and this evidence is directly related to the pulmonary
tropism of this virus; interstitial pneumonia may be dangerous
and lead to respiratory failure and also death if not treated
successfully. Thus, an early detection of lung involvement
from COVID-19 is mandatory and potentially useful to treat
these patients effectively. This is even more crucial in asymp-
tomatic or paucity symptomatic patients, which represent the
majority of patients affected by COVID-19 andmay be source
of infection spread accidentally.
Our results suggest the idea that [18F]FDG PET/CTmay be
an indirect way to detect asymptomatic patients suspected for
Table 3 Summary of the main
radiological and metabolic
features of patients with
interstitial pneumonia detected
during “COVID” period (n = 284)
n (%) Mean (range)
CT features
Laterality
Monolateral lung abnormalities 139 (49%)
Right side 71
Left side 68
Bilateral lung abnormalities 145 (51%)










Only GGO 148 (52%)
Only consolidation areas 14 (5%)
GGO+consolidation areas 117 (41%)
Other 5 (2%)




Bronchial wall thickening 68 (24%)
Crazy paving pattern 118 (42%)
Air bronchogram sign 109 (38%)
Pleural effusion 44 (15%)
Enlarged mediastinal lymph nodes 169 (59.5%)
PET features
FDG-positive lung alterations 169 (59%)
SUVmax lung alterations 4.1 (0.9–14.6)
SUVmean lung alterations 2.6 (0.7–10)
Lesion to liver SUVmax ratio lung alterations 1.4 (0.3–4.7)
Lesion to blood pool SUVmax ratio lung alterations 1.9 (0.3–6.8)
FDG-positive mediastinal lymph nodes 106 (37%)
CT, computed tomography; PET, positron emission tomography; RUL, right upper lobe; RML, right medium
lobe; RLL, right lower lobe; LUL, left upper lobe; Li, lingula; LLL, left lower lobe; GGO, ground-glass opacity;
SUV, standardized uptake value
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COVID-19 infection and lead them to subsequent analyses
(such as diagnostic chest CT and/or RT-PCR test) to identify
infectious patients.
Of course, the detection of interstitial pneumonia
suspected for COVID-19 is done with the help of CT.
Now, almost all PET scanners included CT as part of
tomography. Thus, an accurate analysis of CT images
seems to be mandatory also for nuclear medicine physi-
cians with the aim of integrating morphological and met-
abolic data in the same moment. As reported before
[16–19], we defined viral interstitial pneumonia suspected
for COVID-19 infection if pulmonary infiltrates, GGOs,
and subpleural pseudo-nodular mixed ground-glass and
consolidation areas were present at CT of PET.
The typical CT signs of interstitial pneumonia suspi-
cious for COVID-19 are ground-glass opacities and/or pul-
monary consolidation areas as demonstrated by our data: in
our population, only GGOs were present in 52% of cases,
GGOs associated with consolidation areas in 41% of cases
and only consolidation areas in 5%. These data are similar
to previously published [21–24]. Theoretically, also rarer
lung alterations are possible (2% in our analysis) like nod-
ular areas. In our population, there was a similar pulmo-
nary spread of lung alterations: in 51% of patients, both the
lungs were involved, in contrast with 49% with unilateral
disease. This evidence is partially in contrast with previous
reports [21–24] where a bilateral disease was often report-
ed. This discrepancy may be probably explained by the
early phase of COVID-19 infection detected by our scans,
performed in all asymptomatic patients, thus with no clin-
ical evidence of COVID-19 disease at the time of PET/CT
scan. However, in most cases (65%), more than two lobes
were hit by lung lesions, and there was a prevalence for
lower lobes.
Of course, radiological or metabolic features at PET/CT
were not specific for COVID-19, and they might not be ap-
plied for the differential diagnosis of pulmonary infections or
inflammatory diseases. High-resolution chest CT remains the
most accurate imaging tool to study COVID-19 interstitial
pneumonia; until now, there are no findings suggesting an
added value of [18F]FDG PET/CT compared to chest CT in
the management or outcome of patients with COVID-19 in-
fection. Furthermore, [18F]FDG PET/CT is surely a
more complex tool than chest CT leading to a possible
increased risk of disease spreading due to the longer
time of [18F]FDG PET/CT procedure. However, acci-
dental detection of lung alterations suspected for
COVID-19 may be recognized also with [18F]FDG
PET/CT, and in these cases, [18F]FDG PET/CT could
be considered an indirect way to suspect COVID-19
infection.
COVID-19-related interstitial pneumoniawas [18F]FDG-
avid in most cases with heterogeneous [18F]FDG uptake; in
our analysis, we reported an FDG avidity of 59% with an
average SUVmax of 4.1 (range 0.9–14.6) and an average
SUVmean of 2.6 (range 0.7–10). Instead, mediastinal lymph
node involvement at PET/CTwas discovered in only 37% of
all patients studied during the COVID period. These evi-
dences underlined the aggressiveness of interstitial pneumo-
nia which reflect the highmetabolic activity at PET andwere
similar to other studies [16–19].
The findings of an increased FDG uptake in pulmo-
nary or lymph nodal lesions in patients with COVID-19
infection are not unexpected as acute inflammatory con-
ditions and infectious pulmonary alterations are usually
characterized by increased 18F-FDG uptake [25]. The
ability of [18F]FDG PET/CT to detect areas of infection
and inflammation is mainly associated with the glyco-
lytic activity of the cells involved in the inflammatory
process. In this regard, it has already been demonstrated
that cells involved in infection and inflammation are
mainly neutrophils and monocyte/macrophages, which
are able to express high levels of glucose transporters
and hexokinase activity. It was demonstrated that inter-
stitial pneumonia in COVID-19 patients was character-
ized by alveolar cell damage which is a consequence of
a systemic hyperinflammation condition defined as mac-
rophage activation syndrome or cytokine storm [26–28];
the alveolar macrophages produce pro-inflammatory cy-
tokines and chemokines, thus resulting in a cytokine
storm.
Our results showed a higher rate of interstitial pneumo-
nia during the COVID period compared with the pre-
COVID and control periods, in agreement with previous
local results [16–19], but evaluating a larger population
and representative of Italy. This national evidence was
confirmed also analyzing macro-areas like Northern Italy
and Southern Italy–Islands. On the other hand, when an-
alyzing data from Central Italy, a higher rate of interstitial
pneumonia during COVID time was reported but not sta-
tistically different compared with the other periods. These
results may be explained by the low diffusion of the virus
in Central Italy in the period analyzed and the small num-
ber of PET/CT scans performed in the same period in the
centers recruited in Central Italy (lower than the Northern
and Southern). These results confirmed the concept that
the rates of incidental pneumonia findings were directly
related to the prevalence of COVID-19 in different coun-
tries and regions. The highest prevalence of interstitial
pneumonia was registered in Northern Italy, the region
most affected in March 2020 by the infection.
Instead, when comparing pre-COVID and control pe-
riods, no significant differences in interstitial pneumonia
detection were observed, underlying that probably the
spread of COVID-19 in January and February 2020 in
Italy was not so significant.
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The analysis on the subgroups of patients with FDG-
avid or not FDG-avid interstitial pneumonia confirmed
the same evidences with a significant higher prevalence
in the COVID period.
Our results stressed strongly that nuclear medicine
physicians should pay attention to incidental CT findings
of interstitial pneumonia (especially when morphological
pattern is suspected for COVID-19 infection) detected
with [18F]FDG PET/CT [29, 30], and these reports might
help to recognize early COVID-19 cases guiding the sub-
sequent management. Nuclear medicine physicians and
staff should be on alert since incidental abnormal find-
ings suspicious for COVID-19 may occur on [18F]FDG




with interstitial pneumonia detected during the COVID peri-
od;thiswasduetothedifficultiesinperformingRT-PCRtestin
all cases related to the absence of swaps and reagents, the dif-
ferentprotocolsbetweenregionsincaseofsuspectedinfection
inasymptomaticpatients,andtheoverbookingofsomehealth
facilities or similar during the pandemic. However, the
higher incidence of interstitial pneumonia in the
COVID period and the majority of patients who per-
formed RT-PCR that resulted positive for COVID-19
infection may be considered indirect signs suspicious
of COVID infection.
Moreover, several studies showed the high accuracy of
chest CT in comparison with RT-PCR in the diagnosis of
COVID-19 [8, 31] and the low sensitivity of RT-PCR.
Other limitations of this work were the retrospective design
of the study, the heterogeneity in patient enrollment at the
national level with geographic differences (high adhesion in
northern centers), and the arbitrary choice of different inter-
vals of time of the three periods analyzed also due to organi-
zation reasons.
In conclusion, with this study, we have demonstrated
that during the COVID-19 pandemic, a statistically sig-
nificant increase of interstitial pneumonia at [18F]FDG
PET/CT compared with a pre-COVID period and a con-
trol COVID-19-free period was registered in a country
with high prevalence of infection. These findings were
directly associated with the geographic virus diffusion
with high rate in northern regions. In most cases, inter-
stitial pneumonia suspicious for COVID-19 was FDG-
avid. This is the first study that represents a national
experience in a country with high prevalence of
COVID-19 infection.
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